ubmslateDI-logo-ubm

DI Mobile Menu

Search form

Topics:

Contrast Agents

Contrast Agents

Recent FDA review process of inconclusive clinical studies creates a potentially unhealthy decision-making environment for patients needing gadolinium-enhanced MRIs.

Imaging with gadolinium does not put patients at risk for adverse neurologic outcomes later in life.

Macrocyclic GBCAs in nonenhanced T1 signal intensity pediatric brain tissue.

When faced with the possibility of missed findings, would patients generally agree to consuming oral contrasts?

MRI and CT with contrast provide no greater risk of toxicity for neonates with normal renal system.

Traces of gadolinium used for MR imaging can be found years later, even in pathologically normal brain tissue.

Cost and safety of using contrast-enhanced ultrasound for children.

Pages

Subscribe to Contrast Agents on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.